Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Virology |
| Vol/bind | 78 |
| Udgave nummer | 23 |
| Sider (fra-til) | 12996-3006 |
| Antal sider | 10 |
| ISSN | 0022-538X |
| DOI | |
| Status | Udgivet - 2004 |
Bibliografisk note
Keywords: Anti-HIV Agents; Antibodies, Monoclonal; Calcium; Chemokine CXCL12; Chemokines, CC; Chemokines, CXC; Chemotaxis; HIV; Heterocyclic Compounds; Humans; Pyridines; Receptors, CCR5; Receptors, CXCR4; Virus ReplicationAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. / Princen, Katrien; Hatse, Sigrid; Vermeire, Kurt; Aquaro, Stefano; De Clercq, Erik; Gerlach, Lars-Ole; Rosenkilde, Mette; Schwartz, Thue W; Skerlj, Renato; Bridger, Gary; Schols, Dominique.
I: Journal of Virology, Bind 78, Nr. 23, 2004, s. 12996-3006.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist
AU - Princen, Katrien
AU - Hatse, Sigrid
AU - Vermeire, Kurt
AU - Aquaro, Stefano
AU - De Clercq, Erik
AU - Gerlach, Lars-Ole
AU - Rosenkilde, Mette
AU - Schwartz, Thue W
AU - Skerlj, Renato
AU - Bridger, Gary
AU - Schols, Dominique
N1 - Keywords: Anti-HIV Agents; Antibodies, Monoclonal; Calcium; Chemokine CXCL12; Chemokines, CC; Chemokines, CXC; Chemotaxis; HIV; Heterocyclic Compounds; Humans; Pyridines; Receptors, CCR5; Receptors, CXCR4; Virus Replication
PY - 2004
Y1 - 2004
N2 - Here we report that the N-pyridinylmethyl cyclam analog AMD3451 has antiviral activity against a wide variety of R5, R5/X4, and X4 strains of human immunodeficiency virus type 1 (HIV-1) and HIV-2 (50% inhibitory concentration [IC(50)] ranging from 1.2 to 26.5 microM) in various T-cell lines, CCR5- or CXCR4-transfected cells, peripheral blood mononuclear cells (PBMCs), and monocytes/macrophages. AMD3451 also inhibited R5, R5/X4, and X4 HIV-1 primary clinical isolates in PBMCs (IC(50), 1.8 to 7.3 microM). A PCR-based viral entry assay revealed that AMD3451 blocks R5 and X4 HIV-1 infection at the virus entry stage. AMD3451 dose-dependently inhibited the intracellular Ca(2+) signaling induced by the CXCR4 ligand CXCL12 in T-lymphocytic cells and in CXCR4-transfected cells, as well as the Ca(2+) flux induced by the CCR5 ligands CCL5, CCL3, and CCL4 in CCR5-transfected cells. The compound did not interfere with chemokine-induced Ca(2+) signaling through CCR1, CCR2, CCR3, CCR4, CCR6, CCR9, or CXCR3 and did not induce intracellular Ca(2+) signaling by itself at concentrations up to 400 microM. In freshly isolated monocytes, AMD3451 inhibited the Ca(2+) flux induced by CXCL12 and CCL4 but not that induced by CCL2, CCL3, CCL5, and CCL7. The CXCL12- and CCL3-induced chemotaxis was also dose-dependently inhibited by AMD3451. Furthermore, AMD3451 inhibited CXCL12- and CCL3L1-induced endocytosis in CXCR4- and CCR5-transfected cells. AMD3451, in contrast to the specific CXCR4 antagonist AMD3100, did not inhibit but enhanced the binding of several anti-CXCR4 monoclonal antibodies (such as clone 12G5) at the cell surface, pointing to a different interaction with CXCR4. AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction.
AB - Here we report that the N-pyridinylmethyl cyclam analog AMD3451 has antiviral activity against a wide variety of R5, R5/X4, and X4 strains of human immunodeficiency virus type 1 (HIV-1) and HIV-2 (50% inhibitory concentration [IC(50)] ranging from 1.2 to 26.5 microM) in various T-cell lines, CCR5- or CXCR4-transfected cells, peripheral blood mononuclear cells (PBMCs), and monocytes/macrophages. AMD3451 also inhibited R5, R5/X4, and X4 HIV-1 primary clinical isolates in PBMCs (IC(50), 1.8 to 7.3 microM). A PCR-based viral entry assay revealed that AMD3451 blocks R5 and X4 HIV-1 infection at the virus entry stage. AMD3451 dose-dependently inhibited the intracellular Ca(2+) signaling induced by the CXCR4 ligand CXCL12 in T-lymphocytic cells and in CXCR4-transfected cells, as well as the Ca(2+) flux induced by the CCR5 ligands CCL5, CCL3, and CCL4 in CCR5-transfected cells. The compound did not interfere with chemokine-induced Ca(2+) signaling through CCR1, CCR2, CCR3, CCR4, CCR6, CCR9, or CXCR3 and did not induce intracellular Ca(2+) signaling by itself at concentrations up to 400 microM. In freshly isolated monocytes, AMD3451 inhibited the Ca(2+) flux induced by CXCL12 and CCL4 but not that induced by CCL2, CCL3, CCL5, and CCL7. The CXCL12- and CCL3-induced chemotaxis was also dose-dependently inhibited by AMD3451. Furthermore, AMD3451 inhibited CXCL12- and CCL3L1-induced endocytosis in CXCR4- and CCR5-transfected cells. AMD3451, in contrast to the specific CXCR4 antagonist AMD3100, did not inhibit but enhanced the binding of several anti-CXCR4 monoclonal antibodies (such as clone 12G5) at the cell surface, pointing to a different interaction with CXCR4. AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction.
U2 - 10.1128/JVI.78.23.12996-13006.2004
DO - 10.1128/JVI.78.23.12996-13006.2004
M3 - Journal article
C2 - 15542651
VL - 78
SP - 12996
EP - 13006
JO - Journal of Virology
JF - Journal of Virology
SN - 0022-538X
IS - 23
ER -